| Objective: The expression of plasma adiponectin(APN)in patients with chronic heart failure(CHF)was measured by targeted proteomics so as to explore the clinical values of APN and NT proBNP for diagnosis and prediction in the patients with CHF.Methods: This study was a prospective observational study.Through targeted quantitative proteomics detection,the plasma adiponectin levels were found to be elevated in CHF group(n=10)when compared with the control(CON)group(n=10).The enzyme-linked immunosorbent assay(ELISA)was used to quantitatively detect plasma APN levels in CHF group(n=48)and CON group(n=40).The relationship between concentrations of plasma APN/NT-proBNP and LVEF,and the relationship between the levels of APN/Hb and ALB were compared in the heart failure group,and their correlations were analyzed.According to NYHA classification,the patients of CHF group were divided into three subgroups: 15 patients in subgroup A(II),14 in subgroup B(III),and 19 in subgroup C(IV).Changes in plasma APN,NT-proBNP,and LVEF were compared among the three subgroups.Patients of CHF group were followed up regularly,and plasma APN,NT-proBNP and LVEF levels were collected.Alterations of plasma APN,NT-proBNP and LVEF levels were compared before and 3-6 months after treatment.Results: A total of 108 patients were enrolled,of whom 58 were in the CHF group and50 in the control group.(1)Through targeted quantitative proteomics detection,plasma APN was found to be elevated in comparison of CHF group(n=10)with CON group(n=10).The samples were then subjected to ELISA for verification.Plasma level of APN [(23.08±9.39)μg/ml] in the CHF group(n=48)was significantly higher than that of the CON group[(12.06±3.28)μg/ml,(n=10)],(P<0.05).(2)By data analyses of the CHF group(n=48),we found that the plasma APN level was positively correlated with the plasma Lg(NT-proBNP)level(r= 0.77,P <0.01)but negatively correlated with LVEF(r =﹣0.62,P <0.01),Hb(r=﹣0.47,P <0.01)and ALB(r=﹣0.45,P<0.01).(3)Analysis of CHF subgroup patients whowed that plasma APN level [II(15.52±6.58)μg/ml,III(22.90±6.65)μg/ml and IV(29.20±8.80)μg/ml)] significantly increased with increase of cardiac function grading(P all <0.05).The NT-proBNP level [II 786.00(567.00,1253.00)pg/ml,III 5455.00(4134.75,5692.25)pg/ml and IV 8958.00(6789.00,13789.00)pg/ml] also increased remarkably with increasing of cardiac function grading(P all <0.05).The LVEF level [II(44.27±4.08)%,III(38.93±6.56)% and IV(32.11±8.39)%] decreased significantly with increase of the grading(P all<0.05).(4)In CHF group,the plasma APN level before and after treatments [before treatment(23.08±9.39)μg/ml,3 months(17.72±6.09)μg/ml,6 months(14.24±4.92)μg/ml]gradually decreased(P all<0.05).The NT-proBNP levels before treatments [5455.00(1256.00,8552.25)pg/ml] and 3 months [3461.50(1159.00,4673.00)pg/ml] and 6months after treatments [1267.50(568.00,2196.00)pg/ml] also gradually decreased(P all<0.05).LVEF concentration before treatments [(37.90 ± 8.40)%] and 3 months[(42.17±7.03)%] and 6 months after treatments [(46.13±7.15)%] gradually increased(P all<0.05).Conclusions:1.Plasma APN may increase in the patients with chronic heart failure(CHF)which is positively correlated with NT-proBNP level,but negatively correlated with the levels of LVEF,Hb or ALB,respectively.2.Plasma APN and NT-proBNP levels are closely associated with the extent of cardiac dysfunction.3.Plasma APN concentration may be a useful biomarker for prediction,progression,diagnosis,and prognosis in the patients with CHF. |
PDF Full Text Request